Loading...
Pablo Legorreta* received $0 in total compensation as Chief Executive Officer of Royalty Pharma plc in FY2023. Source: SEC DEF 14A.
In fiscal year 2023, Pablo Legorreta*, Chief Executive Officer of Royalty Pharma plc (RPRX), received total compensation of $0.
Pablo Legorreta*'s compensation breakdown includes:.
Royalty Pharma plc's top 5 named executive officers received combined total compensation of $18.2 million in fiscal year 2023.
The named executive officers disclosed in Royalty Pharma plc's 2023 proxy statement are:Pablo Legorreta* (Chief Executive Officer) with total compensation of $0, Terrance Coyne (Executive Vice President & Chief Financial Officer) with total compensation of $4.6 million, Christopher Hite (Executive Vice President & Vice Chairman) with total compensation of $4.6 million, George Lloyd (Executive Vice President Investments & Chief Legal Officer) with total compensation of $4.6 million, and Marshall Urist (M.D., Ph.D.Executive Vice President, Research & Investments) with total compensation of $4.6 million.
Chief Executive Officer
Based on DEF 14A filed 2024-04-25 · FY2023
Team view
5 executives
Chief Executive Officer
Total PayFY2023
$0
Executive Vice President & Chief Financial Officer
Total PayFY2023
$4.6M
Executive Vice President & Vice Chairman
Total PayFY2023
$4.6M
Executive Vice President Investments & Chief Legal Officer
Total PayFY2023
$4.6M
M.D., Ph.D.Executive Vice President, Research & Investments
Total PayFY2023
$4.6M
FY2023 total compensation breakdown
$0 total compensation
An AI summary will appear here once the pay verdict loads above.
Pay changes vs. stock performance
Recent insider trades by officers and directors
~80 trades
For analysts and deep research
Historical compensation data from latest proxy filing
| Year | Executive | Salary | Bonus & Incentive | Stock Awards | Option Awards | Other Adj. | Total |
|---|---|---|---|---|---|---|---|
| 2023 | Pablo Legorreta* Chief Executive Officer | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
Salary = base cash pay. Bonus & Incentive combines annual bonus and non-equity plans. Equity amounts are grant-date fair values. Other Adj. captures pension changes, perquisites, and any reconciliation items so the total matches the reported figure.
Get one email when new executive compensation data is filed and processed.